AR248167A1 - Molecula de adn recombinante que codifica las subunidades de la toxina del colera y un procedimiento de obtencion de analogos recombinantes de la subunidad de la toxina del colera y de una vacuna - Google Patents

Molecula de adn recombinante que codifica las subunidades de la toxina del colera y un procedimiento de obtencion de analogos recombinantes de la subunidad de la toxina del colera y de una vacuna

Info

Publication number
AR248167A1
AR248167A1 AR92322268A AR32226892A AR248167A1 AR 248167 A1 AR248167 A1 AR 248167A1 AR 92322268 A AR92322268 A AR 92322268A AR 32226892 A AR32226892 A AR 32226892A AR 248167 A1 AR248167 A1 AR 248167A1
Authority
AR
Argentina
Prior art keywords
recombinant dna
cholera toxin
toxin subunit
subunit analogs
arginina
Prior art date
Application number
AR92322268A
Other languages
English (en)
Original Assignee
Amgen Inc
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Univ Southern California filed Critical Amgen Inc
Application granted granted Critical
Publication of AR248167A1 publication Critical patent/AR248167A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/909—Vibrio

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

UNA MOLECULA DE ADN RECOMBINANTE QUE CODIFICA UN ANALOGO DE LA SUBUNIDAD A O A1 CATALITICA DE LA TOXINA DEL COLERA, QUE COMPRENDE UNA MUTACION DE SITIO ESPECIFICO EN UNO O MAS SITIOS DE DICHA SUBUNIDAD ELEGIDA A PARTIR DE 7-ARGININA, 11-ARGININA, 9-ACIDO ASPARTICO, 44-HISTIDINA, 70-HISTIDINA, 112 ACIDO GLUTAMICO, Y UN TRUNCADO DE LA PORCION CARBOXILO-TERMINAL QUE COMIENZA EN EL 179-TRIPTOFANO, QUE TIENE UNA ACTIVIDAD REDUCIDA O NO CATALITICA ASOCIADA CON LA REACTOGENICIDAD DE LA TOXINA DEL COLERA.
AR92322268A 1991-05-02 1992-05-04 Molecula de adn recombinante que codifica las subunidades de la toxina del colera y un procedimiento de obtencion de analogos recombinantes de la subunidad de la toxina del colera y de una vacuna AR248167A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69473391A 1991-05-02 1991-05-02

Publications (1)

Publication Number Publication Date
AR248167A1 true AR248167A1 (es) 1995-06-30

Family

ID=24790064

Family Applications (1)

Application Number Title Priority Date Filing Date
AR92322268A AR248167A1 (es) 1991-05-02 1992-05-04 Molecula de adn recombinante que codifica las subunidades de la toxina del colera y un procedimiento de obtencion de analogos recombinantes de la subunidad de la toxina del colera y de una vacuna

Country Status (18)

Country Link
US (2) US5874287A (es)
EP (1) EP0584284B9 (es)
JP (1) JP3242106B2 (es)
KR (1) KR100249888B1 (es)
CN (1) CN1067679A (es)
AR (1) AR248167A1 (es)
AT (1) ATE199393T1 (es)
AU (1) AU665013B2 (es)
CA (1) CA2102105A1 (es)
DE (1) DE69231708T2 (es)
DK (1) DK0584284T3 (es)
ES (1) ES2156110T3 (es)
GR (1) GR3035724T3 (es)
IL (1) IL101715A (es)
MX (1) MX9202030A (es)
NZ (1) NZ242539A (es)
WO (1) WO1992019265A1 (es)
ZA (1) ZA923162B (es)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043057A (en) * 1988-09-16 2000-03-28 Vitec Aktiebolag Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
IT1253009B (it) * 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US6436407B1 (en) 1994-08-26 2002-08-20 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic adjuvant
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
GB9603314D0 (en) * 1996-02-16 1996-04-17 Biocine Spa Immunogenic detoxified mutant toxins
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
CA2301942C (en) 1997-08-27 2011-05-31 Chiron Corporation Molecular mimetics of meningococcal b epitopes
US6033673A (en) * 1998-03-18 2000-03-07 The Administrators Of Tulane Educational Fund Double mutant enterotoxin for use as an adjuvant
AU3089599A (en) * 1998-03-18 1999-10-11 Smithkline Beecham Corporation Production of purified mutant enterotoxin for use as an adjuvant
EP2261355A3 (en) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
AU770498B2 (en) 1998-06-19 2004-02-26 Merieux Oravax LT and CT in parenteral immunization methods against helicobacter infection
BR9914160A (pt) * 1998-09-30 2001-06-26 American Cyanamid Co Composição antigênica, método para aumentar a capacidade de uma composição antigênica que contenha um antìgeno selecionado de uma bactéria, vìrus, fungo ou parasita patogênicos, do haemophilus influenzae, do helicobacter pylori, do vìrus sincicial respiratório, do rotavìrus, e, do vìrus simples do herpes para evocar a resposta imune de um hospedeiro vertebrado, plasmìdeo, célula hospedeira, método para produzir uma holotoxina do cólera mutante imunogênica, e, uso de uma quantidade auxiliar eficaz de uma holotoxina do cólera mutante
CN1191357C (zh) * 1998-12-22 2005-03-02 博伊斯·汤普生植物研究所 口服的免疫原性细菌肠毒素在转基因植物中的表达
US6602705B1 (en) 1998-12-31 2003-08-05 Chiron Corporation Expression of HIV polypeptides and production of virus-like particles
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
JP2002537355A (ja) 1999-02-26 2002-11-05 カイロン コーポレイション 抗原の粘膜送達のための生体接着剤およびアジュバントの使用
EP1574210B1 (en) 1999-02-26 2016-04-06 Novartis Vaccines and Diagnostics, Inc. Microemulsions with adsorbed macromolecules
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
EP1272210A1 (en) * 2000-03-17 2003-01-08 The Uab Research Foundation Chimeric nontoxic mutants of enterotoxins as mucosal adjuvants for cell-mediated or humoral immunity
US7063852B2 (en) 2000-05-19 2006-06-20 The Administrators Of The Tulane Educational Fund Hybrid LT-A/CT-B holotoxin for use as an adjuvant
AU2001292610A1 (en) * 2000-09-08 2002-03-22 University Of Maryland Biotechnology Institute Genetically engineered co-expression dna vaccines, construction methods and uses thereof
US20030162733A1 (en) * 2000-11-27 2003-08-28 Haynes Joel R. Nucleic acid adjuvants
WO2002080982A2 (en) 2001-01-12 2002-10-17 Chiron Corporation Nucleic acid mucosal immunization
CA2444133A1 (en) 2001-04-16 2002-10-24 Wyeth Holdings Corporation Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
CN1541111A (zh) * 2001-06-07 2004-10-27 ���Ͽع����޹�˾ 作为佐剂的霍乱全毒素的突变形式
EP1404368B1 (en) 2001-06-07 2009-12-09 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
US20030198621A1 (en) 2001-07-05 2003-10-23 Megede Jan Zur Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CA2476626A1 (en) 2002-02-20 2003-08-28 Chiron Corporation Microparticles with adsorbed polypeptide-containing molecules
KR100981471B1 (ko) 2002-03-15 2010-09-10 더 큐레이터스 오브 더 유니버시티 오브 미주리 효소 활성이 감소된 형별불능 헤모필러스 인플루엔자의ｐ4 변형 단백질
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
CA2500661A1 (en) 2002-10-01 2004-04-15 Chiron Corporation Anti-cancer and anti-infectious disease compositions and methods for using same
EP2263687B1 (en) 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
EP2179729B1 (en) 2003-06-02 2016-07-20 GlaxoSmithKline Biologicals SA Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
US8071652B2 (en) 2003-08-21 2011-12-06 The Board Of Regents Of The University Of Texas System Method of treating irritable bowel syndrome
GB0325494D0 (en) * 2003-10-31 2003-12-03 Sbl Vaccin Ab Expression system
EP2460813A1 (en) 2003-12-17 2012-06-06 Janssen Alzheimer Immunotherapy A beta immunogenic peptide carrier conjugates and methods of producing same
JP4764830B2 (ja) 2003-12-17 2011-09-07 ワイス・エルエルシー 免疫原性ペプチド担体コンジュゲートおよびその生産法
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
EP2301957A3 (en) 2004-05-21 2011-05-18 Wyeth LLC Altered fibronectin-binding protein of staphylococcus aureus
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
AU2005333603A1 (en) 2004-10-21 2007-01-04 Wyeth Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens
CA2585672A1 (en) 2004-11-01 2006-05-11 Novartis Vaccines And Diagnostics Inc. Combination approaches for generating immune responses
CN102716480B (zh) 2005-04-08 2023-03-21 惠氏有限责任公司 多价肺炎球菌多糖-蛋白质缀合物组合物
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8926993B2 (en) 2006-07-17 2015-01-06 Aduro Biotech Methods and compositions using Listeria for enhancing immunogenicity by prime boost
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP2244695A1 (en) 2007-12-07 2010-11-03 Novartis AG Compositions for inducing immune responses
US9415006B2 (en) 2008-05-23 2016-08-16 The Regents Of The University Of Michigan Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
EP2328928A2 (en) 2008-08-25 2011-06-08 Dana-Farber Cancer Institute, Inc. Conserved influenza hemagglutinin epitope and antibodies thereto
AU2009296458A1 (en) 2008-09-26 2010-04-01 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
NZ614064A (en) 2008-11-05 2015-04-24 Wyeth Llc Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease
AU2009314091B2 (en) 2008-11-12 2015-05-14 Theraclone Sciences, Inc. Human M2e peptide immunogens
WO2010078556A1 (en) 2009-01-05 2010-07-08 Epitogenesis Inc. Adjuvant compositions and methods of use
WO2010104883A1 (en) 2009-03-09 2010-09-16 Molecular Express, Inc. Methods and compositions for liposomal formulation of antigens and uses thereof
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
US20100316673A1 (en) 2009-06-16 2010-12-16 The Regents Of The University Of Michigan Nanoemulsion vaccines
JP5977737B2 (ja) 2010-05-23 2016-08-24 アデュロ バイオテック 癌の補助薬物療法でリステリアを使用する方法および組成物
SI3170508T1 (sl) 2010-06-04 2020-01-31 Wyeth Llc Formulacije cepiva
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
HRP20210242T4 (hr) 2010-08-23 2024-05-10 Wyeth Llc Stabilne formulacije antigena iz bakterije neisseria meningitidis rlp2086
CN103096920B (zh) 2010-09-10 2016-03-23 惠氏有限责任公司 脑膜炎奈瑟球菌orf2086抗原的非脂质化变体
SE535625C2 (sv) * 2010-10-28 2012-10-16 Toleranzia Ab Nya kompositioner och förfaranden för behandling av autoimmuna och allergiska sjukdomar
EA034702B1 (ru) 2011-04-26 2020-03-10 Молекулар Экспресс, Инк. Липосомные композиции
CN103717235A (zh) 2011-06-24 2014-04-09 埃皮托吉尼西斯有限公司 作为抗原特异性免疫调节剂的包含选择的载体、维生素、单宁和类黄酮的组合的药物组合物
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
BR112014011560A2 (pt) 2011-11-14 2017-05-09 Novartis Ag complexos imunogênicos de carbômeros polianiônicos e polipeptídeos env, e métodos de fabricação e uso dos mesmos
BR122016004924A2 (pt) 2012-03-09 2019-07-30 Pfizer Inc. Polipeptídeo isolado e composições imunogênicas compreendendo os mesmos
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
EP2870238A4 (en) 2012-07-05 2016-03-09 Ohio State Innovation Foundation COMPOSITIONS AND METHODS ASSOCIATED WITH VIRAL VACCINES
CN104854128A (zh) 2012-07-19 2015-08-19 硕腾有限责任公司 牛流感病毒组合物
AU2013295770A1 (en) 2012-07-27 2015-01-29 Zoetis Services Llc Tick toxin compositions
MX363511B (es) 2012-08-16 2019-03-26 Pfizer Proceso de glucoconjugación y composiciones.
BR112015009229B1 (pt) 2012-10-24 2021-07-20 Platelet Targeted Therapeutics, Llc Composição tendo como alvo a expressão de genes para plaquetas, uso de uma célula tronco compreendendo a referida composição para tratar hemofilia e método in vitro ou ex vivo para gerar uma célula tronco modificada
KR20140075201A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
AU2014234982A1 (en) 2013-03-15 2015-09-24 Zoetis Services Llc Cross-protection of bovines against B. trehalosi infection by a multi-valent vaccine
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP6306700B2 (ja) 2013-11-01 2018-04-04 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ アルブミン改変体及びその使用
CA2929126C (en) 2013-11-13 2020-01-07 University Of Oslo Outer membrane vesicles and uses thereof
EP3069138B1 (en) 2013-11-15 2019-01-09 Oslo Universitetssykehus HF Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
SI3096786T1 (sl) 2014-01-21 2021-09-30 Pfizer Inc. Kapsularni polisaharidi streptococcus pneumoniae in njihovi konjugati
JP6612260B2 (ja) 2014-01-21 2019-11-27 ファイザー・インク 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）莢膜多糖およびそのコンジュゲート
US10668164B2 (en) 2014-02-14 2020-06-02 Pfizer Inc. Immunogenic glycoprotein conjugates
EP3204039B1 (en) 2014-10-10 2022-06-08 The Regents Of The University Of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP4226937A3 (en) 2015-03-05 2023-09-27 Northwestern University Non-neuroinvasive viruses and uses thereof
WO2016179034A2 (en) 2015-05-01 2016-11-10 The Trustees Of The University Of Pennsylvania Methods and compositions for stimulating immune response using potent immunostimulatory rna motifs
WO2017030901A1 (en) 2015-08-14 2017-02-23 Zoetis Services Llc Mycoplasma bovis compositions
US11324816B2 (en) 2015-08-31 2022-05-10 Technovax, Inc. Human respiratory syncytial virus (HRSV) virus-like particles (VLPS) based vaccine
CA3010977A1 (en) 2016-01-11 2017-07-20 Zoetis Services Llc Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
CA3011887A1 (en) 2016-03-14 2017-09-21 Stian FOSS Engineered immunoglobulins with altered fcrn binding
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
WO2017201390A1 (en) 2016-05-19 2017-11-23 The Regents Of The University Of Michigan Novel adjuvant compositions
WO2017210215A1 (en) 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Zika virus vaccine and methods of production
WO2017221072A2 (en) 2016-06-21 2017-12-28 University Of Oslo Hla binding vaccine moieties and uses thereof
WO2017220753A1 (en) 2016-06-22 2017-12-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
EP3269385A1 (en) 2016-07-12 2018-01-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
GB201703529D0 (en) 2017-03-06 2017-04-19 Cambridge Entpr Ltd Vaccine composition
WO2018183666A1 (en) 2017-03-31 2018-10-04 Boston Medical Center Corporation Methods and compositions using highly converved pneumococcal surface proteins
TW201925222A (zh) 2017-06-23 2019-07-01 美商醫院疫苗公司 免疫原性組成物
WO2019048928A1 (en) 2017-09-07 2019-03-14 University Of Oslo VACCINE MOLECULES
US12005112B2 (en) 2017-09-07 2024-06-11 University Of Oslo Vaccine molecules
EP3574915A1 (en) 2018-05-29 2019-12-04 Neovacs Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
AU2020323498A1 (en) 2019-07-31 2022-03-03 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
US20230338530A1 (en) 2020-01-10 2023-10-26 Lg Chem, Ltd. Composition comprising antigen-presenting cell co-expressing mhc and tumor antigen, and cancer treatment using same
CA3165957A1 (en) 2020-01-24 2021-07-29 Thomas K. EQUELS Methods, compositions, and vaccines for treating a virus infection
JP2023522050A (ja) 2020-04-16 2023-05-26 パーイミューン エスエーエス 血管炎の処置のための住血吸虫由来の２８ｋｄａ ｇｓｔタンパク質
EP3900739A1 (en) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein
IL301402A (en) 2020-09-17 2023-05-01 Inst Nat Sante Rech Med An immunogenic product containing a segment of ige for the treatment of inflammatory disorders mediated by ige
WO2022207793A1 (en) 2021-03-31 2022-10-06 Vib Vzw Vaccine compositions for trypanosomatids
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328209A (en) * 1979-04-11 1982-05-04 Board Of Regents, The University Of Texas System Cholera vaccine
US4666837A (en) * 1982-05-24 1987-05-19 Smithkline-Rit DNA sequences, recombinant DNA molecules and processes for producing the A and B subunits of cholera toxin and preparations containing so-obtained subunit or subunits
US4935364A (en) * 1983-03-04 1990-06-19 Swiss Serum And Vaccine Institute Berne Method of isolating restriction fragment deletions in vibrio cholerae and products thereof
US4882278A (en) * 1983-04-29 1989-11-21 President And Fellows Of Harvard College Non-toxinogenic vibrio cholerae mutants

Also Published As

Publication number Publication date
DE69231708D1 (de) 2001-04-05
ES2156110T3 (es) 2001-06-16
WO1992019265A1 (en) 1992-11-12
ATE199393T1 (de) 2001-03-15
IL101715A0 (en) 1992-12-30
DK0584284T3 (da) 2001-06-18
CN1067679A (zh) 1993-01-06
DE69231708T2 (de) 2001-07-05
KR100249888B1 (ko) 2000-04-01
AU665013B2 (en) 1995-12-14
ZA923162B (en) 1993-04-28
AU2293092A (en) 1992-12-21
EP0584284A4 (en) 1995-03-15
IL101715A (en) 2005-06-19
MX9202030A (es) 1993-02-01
US5770203A (en) 1998-06-23
CA2102105A1 (en) 1992-11-03
EP0584284A1 (en) 1994-03-02
JP3242106B2 (ja) 2001-12-25
US5874287A (en) 1999-02-23
GR3035724T3 (en) 2001-07-31
JPH06507551A (ja) 1994-09-01
EP0584284B1 (en) 2001-02-28
EP0584284B9 (en) 2002-11-13
NZ242539A (en) 1993-11-25

Similar Documents

Publication Publication Date Title
AR248167A1 (es) Molecula de adn recombinante que codifica las subunidades de la toxina del colera y un procedimiento de obtencion de analogos recombinantes de la subunidad de la toxina del colera y de una vacuna
DE3588149T2 (de) Rekombinante DNS-Verfahren und dadurch hergestellte Produkte
ATE90360T1 (de) Molekulare klonierung und charakterisierung einer weiteren gen-sequenz, die fuer menschliches relaxin kodiert.
DE3586853D1 (de) Immunologisch aktive peptide, geeignet zur einfuehrung von immunisierung gegen malaria und deren kodierung von genen.
ES2077666T3 (es) Proteina de union a fibronectina y su preparacion.
ATE125568T1 (de) Analoge der untereinheit des von rekombinanter dns abgeleiteten bordetella-toxins.
IT8722078V0 (it) Sauna di vapore con un impianto vaporizzatore posta in una cupola applicata superiormente alla cabina.
DE69020623T3 (de) Glasfrit, verwendbar zur Herstellung von Glashohlkugeln, und daraus hergestellte Glashohlkugeln.
PT615751E (pt) Utilizacao de antagonistas de taquinina no tratamento da emese
DE3777421D1 (de) Hochfester stahl fuer ventilfedern, verfahren zur herstellung des stahles und daraus hergestellte ventilfedern.
MX9307059A (es) Composicion curable, anhidridos utiles en dicha composicion y articulos revestidos.
FI930584A0 (fi) Vetyperoksidiprosessissa käytettävä hydrauskatalyytti ja menetelmä sen valmistamiseksi
ATE154507T1 (de) Dentalwerkstoffe auf basis von (meth)-acrylaten
DE3886517D1 (de) Menschlicher Prourokinase ähnliches Polypeptid.
FR2591115B1 (fr) Element d'appui desinfectant et/ou desodorisant, tel que barre ou poignee.
ATE283924T1 (de) Phospholipase d gen aus pflanzen
PE20000759A1 (es) Gen de la citocroma oxidasa de hidroquinona del tipo bd
FI944563A (fi) Mikro-organismeja, valmistusmenetelmä ja käyttö
CO4230141A1 (es) Acc-sintasa de crucifera y sus usos
IT8722184A0 (it) Tastiera per macchina da scrivere o simili.
DE3784309D1 (de) Punktmatrix-anzeige.
FI920117A (fi) Rekombinant iga-proteas.
DE3777359D1 (de) Aminosaeuresequenz des menschlichen alpha 2-plasmininhibitors und cdns sowie diese aminosaeuresequenz codierende genomische dns.
DE3781865D1 (de) Klonierung von dns, welche einen menschlichen gip-vorlaeufer kodiert und expressionsverfahren des vorlaeufers.
ES2104130T3 (es) Adn hibrido, que codifica una subunidad de una toxina bacteriana con una hemolisina.